The value of a clinical prediction rule for allogeneic transfusion in cardiac surgery

Transfusion

Volumn 46, Issue 7, 2006, Pages 1072-1074

  Tinmouth, Alan T ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; ERYTHROPOIETIN;

ALLOGENEIC BLOOD TRANSFUSION; ANKLE FRACTURE; BLOOD CONSERVATION; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; EDITORIAL; ERYTHROCYTE TRANSFUSION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; OPEN HEART SURGERY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; POSTOPERATIVE HEMORRHAGE; PREDICTION; RELIABILITY; TREATMENT INDICATION;

BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; HEMORRHAGE; HUMANS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 33746508989     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00886.x     Document Type: Editorial

References (14)

1. Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: Myths and realities. Ann Thorac Surg 1996;62:1908-17.
2. Hutton B, Fergusson D, Tinmouth A, et al. Transfusion rates vary significantly amongst Canadian medical centres. Can J Anaesth 2005;52:581-90.
3. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354: 353-65.
4. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006;46:327-38.
5. Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoietin-α to augment preoperative autologous blood donation in elective cardiac surgery. Pharmaeconomics 2000;18:161-71.
6. Aubuchon JP. Cost-effectiveness of preoperative autologous blood donation for orthopedic and cardiac surgeries. Am J Med 1996;101:38s-42s.
7. Laupacis A, Sekar R, Stiell IG. Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA 1997;277:488-94.
8. Alghamdi A, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs Transfusion 2006;46:1120-9.
9. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules: application and methodological standards. N Engl J Med 1985;313:793-9.
10. Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine: blood conservation. N Engl J Med 1997;340:525-33.
11. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005;2:218-29;discussion 229-32.
12. Spiess BD. Risks of transfusion: outcome focus. Transfusion 2004;44:4S-14S.
13. Leal-Noval SR, Jara-Lopez I, Garcia-Garmendia JL, et al. Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients. Anesthesiology 2003;98:815-22.
14. Michalopoulos A, Tzelepis G, Dafni U, Geroulanos S. Determinants of hospital mortality after coronary artery bypass grafting. Chest 1999;115:1598-603.